Financials in USD. Standardized financial statements.
A compact view of how BioCryst Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $874.84M | $450.71M | $331.41M | $270.83M | $157.17M | $17.81M | $48.84M | $20.65M | $25.19M | $26.35M |
| Revenue Growth? | +94.1% | +36.0% | +22.4% | +72.3% | +782.4% | -63.5% | +136.5% | -18.0% | -4.4% | 0.0% |
| Cost of Revenue? | $19.07M | $12.48M | $4.66M | $6.59M | $7.26M | $1.68M | $4.10M | $471,000 | $1.70M | $2.70M |
| Gross Profit? | $855.76M | $438.23M | $326.75M | $264.23M | $149.91M | $16.14M | $44.73M | $20.18M | $23.48M | $23.65M |
| Gross Margin? | +97.8% | +97.2% | +98.6% | +97.6% | +95.4% | +90.6% | +91.6% | +97.7% | +93.2% | +89.8% |
| Operating Expenses? | $514.77M | $440.77M | $430.46M | $412.67M | $327.63M | $190.89M | $144.19M | $114.40M | $80.89M | $72.26M |
| Operating Income? | $340.99M | -$2.54M | -$103.71M | -$148.44M | -$177.72M | -$174.76M | -$99.45M | -$94.22M | -$57.41M | -$48.61M |
| EBITDA? | $347.65M | $12.81M | -$116.33M | -$143.85M | -$121.74M | -$167.56M | -$96.28M | -$90.36M | -$56.51M | -$48.17M |
| Income Before Tax | $267.39M | -$86.95M | -$226.23M | -$244.38M | -$181.81M | -$182.81M | -$108.90M | -$101.25M | -$65.78M | -$55.14M |
| Income Tax Expense | $3.53M | $1.93M | $310,000 | $2.73M | $2.25M | $0 | $0 | $0 | $0 | $0 |
| Net Income? | $263.86M | -$88.88M | -$226.54M | -$247.12M | -$184.06M | -$182.81M | -$108.90M | -$101.25M | -$65.78M | -$55.14M |
| EPS? | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.94 | $-0.98 | $-0.78 | $-0.75 |
| Diluted EPS? | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.94 | $-0.98 | $-0.78 | $-0.75 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality